Nanoform and Orion collaborate on 'nanoformed' APIs

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Many new chemical entities struggle to progress into clinical development due to their physico-chemical properties and respective solubility and bioavailability challenges. This issue is expected to exacerbate as molecular complexity increases in drug discovery.

Nanoform's CESS technology produces nanoformed "designed-for-purpose" API particles, as small as 10 nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability.

This collaboration with Nanoform presents an opportunity to enhance Orion's formulation process and provide poorly soluble molecules with a path to clinical trials.

Dr Juha Kiesvaara, VP Global Pharmaceutical Research at Orion Corporation, believes that using nanoparticles in the range that Nanoform can produce will provide them with a "great opportunity" to simplify the formulation process, develop optimal products and enable poorly soluble molecules to progress into clinic.

"Producing tailored nanoparticles smaller than 200 nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is challenging to do by current pharmaceutical manufacturing techniques or processes. Now that Nanoform has a path to clinical development with their upcoming GMP facility we are excited to see how they can add value to Orion's drug development products," said Dr Juha Kiesvaara.